文献速递糖尿病肥胖与代谢综合征

代谢综合征特征增加2型糖尿病患者主要不良肝脏结局风险

Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2024-01-01

基于瑞典国家登记数据1998至2021年纳入230992例无肝病史的2型糖尿病患者,中位随访9.9年,3215例(1.39%)发生主要不良肝脏结局(MALO)。基线代谢综合征特征超过1项者MALO发生率高于仅2型糖尿病者(aHR 2.33,95%CI 1.53-3.54),且随特征数目增加逐步升高(每增加1项aHR 1.28,95%CI 1.23-1.33);与MALO关联最大的特征为高血压(aHR 2.06,95%CI 1.57-2.71)。

要点

  • 基线代谢综合征特征超过1项者MALO发生率高于仅2型糖尿病者(aHR 2.33,95%CI 1.53-3.54)。
  • MALO发生率随基线代谢综合征特征数目增加而逐步升高(每增加1项aHR 1.28,95%CI 1.23-1.33)。
  • 随访期间新获得代谢综合征特征者MALO发生率逐步升高;高血压与MALO关联最大(aHR 2.06,95%CI 1.57-2.71)。

核心结论

  • 患有或新获得更多代谢综合征特征会增加2型糖尿病患者进展至MALO的发生率。
  • 这些结果可用于为肝病筛查措施提供信息。

研究设计与样本

  • 从瑞典国家登记处识别1998年至2021年无肝病史的2型糖尿病患者。
  • 共纳入230992例患者,中位年龄64岁,58%为男性。
  • 代谢综合征特征包括高血压、低HDL水平、高甘油三酯血症、肥胖和白蛋白尿,此外还有2型糖尿病。
  • MALO事件基于国家登记处行政编码识别至2022年10月31日,数据分析采用Cox回归模型。

主要发现

  • 中位随访9.9年期间,3215例(1.39%)发生MALO。
  • 与基线仅1项代谢综合征特征(仅2型糖尿病)者相比,超过1项特征者MALO发生率更高(aHR 2.33,95%CI 1.53-3.54)。
  • MALO发生率随基线代谢综合征特征数目增加而逐步升高(每增加1项aHR 1.28,95%CI 1.23-1.33)。
  • 随访期间新获得额外代谢综合征特征的患者MALO发生率逐步升高。
  • 与MALO发生关联最大的代谢综合征特征为高血压(aHR 2.06,95%CI 1.57-2.71)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes (T2D) increases the risk for major adverse liver outcomes (MALOs), including cirrhosis and its complications. Patients with T2D frequently have other traits of the metabolic syndrome (MetS). It remains uncertain whether there is a synergistic effect of accumulating MetS traits on future MALO risk. RESEARCH DESIGN AND METHODS: Patients with T2D without a history of liver disease were identified from national registers in Sweden from 1998 to 2021. MetS traits included hypertension, low HDL level, hypertriglyceridemia, obesity, and albuminuria, in addition to T2D. MALO events were identified based on administrative coding from national registers until 31 October 2022. Data were analyzed using Cox regression models. RESULTS: In total, 230,992 patients were identified (median age 64 years; 58% male), of whom 3,215 (1.39%) developed MALOs over a median follow-up of 9.9 years. Compared with patients with one MetS trait (only T2D) at baseline, those with more than one MetS trait had a higher rate of MALOs (adjusted hazard ratio [aHR] 2.33, 95% CI 1.53-3.54). The rate of MALOs increased progressively with increasing numbers of MetS traits at baseline (aHR 1.28 per added trait, 95% CI 1.23-1.33). During follow-up, patients who acquired additional MetS traits had a progressively higher rate of MALOs. The MetS trait with the largest association with incident MALOs was hypertension (aHR 2.06, 95% CI 1.57-2.71). CONCLUSIONS: Having or acquiring additional traits of MetS increase the rate of progression to MALOs in patients with T2D. These results could be used to inform screening initiatives for liver disease.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Shang Y, Grip ET, Modica A, et al. Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes. Diabetes Care. 2024. PMID: 38498331. doi:10.2337/dc23-1937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。